The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma

References

• Kyle R A. Multiple myeloma: review of 869 cases. Mayo Clinic Proceedings 1975; 50: 29–40
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. Mechanism of bone destruction in multiple myeloma: the importance of unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 1989; 7: 1909–1914
   PubMed Web of Science ®Google Scholar
• Calvo M S, Eyre D R, Gundberg C M. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Reviews 1996; 17: 333–368
   PubMed Web of Science ®Google Scholar
• Noguchi M, Noda S. Pyridinolone cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. The Journal of Urology 2001; 166: 1106–1110
   PubMed Web of Science ®Google Scholar
• Horiguchi T, Tachikawa S, Kondo R, Hirose M, Teruya S, Ishibashi A, Banno K. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Japanese Journal of Clinical Oncology 2000; 30: 174–179
   PubMed Web of Science ®Google Scholar
• Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. European Journal of Haematology 1999; 62: 300–306
   PubMed Web of Science ®Google Scholar
• Peest D, Deicher H, Fett W, Harms P, Braun H J, Planker M, et al. Pyridinum cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy—a pilot study of the German Myeloma Treatment Group (GMTG). European Journal of Cancer 1996; 32A: 2053–2057
   PubMed Web of Science ®Google Scholar
• Jakob C, Zavrski I, Heider U, Bollow M, Schulz C O, Fleissner C, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clinical Cancer Research 2003; 9: 3047–3051
   PubMed Web of Science ®Google Scholar
• Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. European Journal of Haematology 2000; 64: 121–129
   PubMed Web of Science ®Google Scholar
• Fonseca R, Trendle M C, Leong T, Kyle R A, Oken M M, Kay N E, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. British Journal of Haematology 2000; 109: 24–29
   PubMed Web of Science ®Google Scholar
• Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. European Journal of Haematology 2002; 69: 37–42
   PubMed Web of Science ®Google Scholar
• Hayasaka A, Iida S, Ohto M. Serum concentrations of the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen in chronic liver disease. Clinica Chimica Acta 1995; 238: 85–90
   PubMed Web of Science ®Google Scholar
• Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. The Journal of Rheumatology 1999; 26: 1250–1256
   PubMed Web of Science ®Google Scholar
• Alexandrakis M G, Passam F H, Malliaraki N, Katachanakis C, Kyriakou D S, Margioris A N. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clinica Chimica Acta 2002; 325: 51–57
   PubMed Web of Science ®Google Scholar
• Woitge H W, Horn E, Keck A V, Auler B, Seibel M J, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clinical Chemistry 2001; 47: 686–693
   PubMed Web of Science ®Google Scholar
• Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clinica Chimica Acta 1996; 253: 61–77
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, Possinger K, Sers C, Krenn V. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002; 99: 4646–4647
   PubMed Web of Science ®Google Scholar
• Heider U, Zavrski I, Jakob C, Bangeroth K, Fleissner C, Langelotz C, et al. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. Journal of Cancer Research and Clinical Oncology 2004; 130: 469–474
   PubMed Web of Science ®Google Scholar